NASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis $95.53 -0.97 (-1.00%) As of 11:38 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Halozyme Therapeutics Stock (NASDAQ:HALO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Halozyme Therapeutics alerts:Sign Up Key Stats Today's Range$95.20▼$97.0150-Day Range$96.50▼$131.1852-Week Range$61.22▼$134.00Volume410,640 shsAverage Volume1.98 million shsMarket Capitalization$10.89 billionP/E Ratio24.31Dividend YieldN/APrice Target$108.18Consensus RatingHold Company Overview Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids. Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners. Its work centers on making selected injectable treatments available through alternative routes of administration.AI Generated. May Contain Errors. Read More Halozyme Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks85th Percentile Overall ScoreHALO MarketRank™: 4.26171823131 of 5 starsHalozyme Therapeutics scored higher than 85% of companies evaluated by MarketBeat, and ranked 61st out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingHalozyme Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on no strong buy ratings, 7 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialHalozyme Therapeutics has a consensus price target of $108.18, representing about 11.9% upside from its current price of $96.67.Amount of Analyst CoverageHalozyme Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Halozyme Therapeutics' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth17.51% Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 17.51% in the coming year, from $8.34 to $9.80 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 24.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.13.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 24.61, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.31.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.38. PEG Ratios below 1 indicate that a company could be undervalued. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.28% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 6.81.Change versus previous monthShort interest in Halozyme Therapeutics has recently decreased by 0.03%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.03 News SentimentHalozyme Therapeutics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for Halozyme Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 13 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat Follows8 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $17,346,093.00 in company stock.Percentage Held by Insiders2.50% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Halozyme Therapeutics' insider trading history. Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HALO Stock News HeadlinesHalozyme Therapeutics Insider Sold Shares Worth $6,000,686, According to a Recent SEC Filing4 hours ago | marketscreener.comMHalozyme Therapeutics (NASDAQ:HALO) Stock: Insider Helen Torley Sells 20,000 SharesNovember 17 at 4:07 AM | insidertrades.comMy $247 scanner for $7Bill Poulos is cutting the price of his $247 Instant Scanner to $7 for Black Friday. It's a one-time payment that covers a full year, with no subscription and no re-bills. Every night after the close, the scanner screens nearly a thousand of America's biggest stocks. It returns a short list of qualifying setups with the exact buy price next to each one. There's nothing to install. If you decide it's not for you, you get the $7 back and keep the scanner for the year.November 17 at 1:00 AM | Profits Run (Ad)Comparing Soligenix (NASDAQ:SNGX) & Halozyme Therapeutics (NASDAQ:HALO)November 14 at 5:05 AM | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Cut to "Hold" at Zacks ResearchNovember 14 at 3:39 AM | americanbankingnews.comHalozyme Therapeutics (HALO) Stock Gets Fair Value Boost After Q3 Analyst RevisionsNovember 12, 2026 | finance.yahoo.comHalozyme Therapeutics (HALO) Stock Looks In Line As ENHANZE Approval LandsNovember 12, 2026 | finance.yahoo.comHalozyme downgraded at Morgan Stanley on valuationNovember 11, 2026 | msn.comSee More Headlines HALO Stock Analysis - Frequently Asked Questions How have HALO shares performed this year? Halozyme Therapeutics' stock was trading at $67.30 at the beginning of 2026. Since then, HALO stock has increased by 43.6% and is now trading at $96.6740. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced its quarterly earnings results on Thursday, November, 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts' consensus estimates of $2.30 by $0.09. The company's quarterly revenue was up 39.1% on a year-over-year basis. Read the conference call transcript. Does Halozyme Therapeutics have any subsidiaries? The following companies are subsidiaries of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH. Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' top institutional shareholders include Boston Partners (2.42%), Congress Asset Management Co. (2.01%), First Trust Advisors LP (1.59%) and William Blair Investment Management LLC (1.42%). Insiders that own company stock include Helen Torley, Michael J Labarre, Matthew L Posard, Bernadette Connaughton, Jeffrey William Henderson, Nicole Labrosse, Mahesh Krishnan, Cortney Caudill and Cortney Caudill. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Halozyme Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Micron Technology (MU), Gilead Sciences (GILD), Intel (INTC), Palantir Technologies (PLTR) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/05/2026Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 11 days, HALO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees423Year Founded1998Price Target and Rating Average Price Target for Halozyme Therapeutics$108.18 High Price Target$149.00 Low Price Target$56.00 Potential Upside/Downside+12.8%Consensus RatingHold Rating Score (0-4)2.46 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$3.93 Trailing P/E Ratio24.41 Forward P/E Ratio9.79 P/E Growth0.38Net Income$316.89 million Net Margins26.93% Pretax Margin36.34% Return on Equity751.81% Return on Assets23.84% Debt Debt-to-Equity Ratio13.50 Current Ratio3.88 Quick Ratio3.60 Sales & Book Value Annual Sales$1.40 billion Price / Sales7.83 Cash Flow$4.55 per share Price / Cash Flow21.10 Book Value($0.48) per share Price / Book-199.85Miscellaneous Outstanding Shares114,010,000Free Float111,160,000Market Cap$10.94 billion OptionableOptionable Beta0.92 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:HALO) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredYour Copy is on Hold (Claim it now)James Altucher, who called NVIDIA in 2008 and SpaceX years before a single share traded, has a new report on E...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.